Which has preferable valuation & earnings, SRZN or WVE?

WAVE Life Sciences has higher revenue and earnings than Surrozen. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 77.93 -$242.03M -$40.55 N/A WAVE Life Sciences $42.73M 24.21 -$204.38M -$1.09 N/A

Does the media favor SRZN or WVE?

In the previous week, Surrozen had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Surrozen and 3 mentions for WAVE Life Sciences. Surrozen's average media sentiment score of 0.59 beat WAVE Life Sciences' score of -0.97 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer JANX or SRZN?

In the previous week, Janux Therapeutics had 4 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Janux Therapeutics and 5 mentions for Surrozen. Janux Therapeutics' average media sentiment score of 0.96 beat Surrozen's score of 0.59 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRZN or FBRX?

In the previous week, Surrozen and Surrozen both had 5 articles in the media. Surrozen's average media sentiment score of 0.59 beat Forte Biosciences' score of 0.38 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SRZN or LXRX?

In the previous week, Surrozen had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Surrozen and 4 mentions for Lexicon Pharmaceuticals. Surrozen's average media sentiment score of 0.59 beat Lexicon Pharmaceuticals' score of 0.22 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Surrozen (SRZN) Competitors

$23.36 -0.61 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$23.25 -0.11 (-0.47%)

As of 04:10 PM Eastern

Compare

SRZN vs. AVTX, WVE, JANX, FBRX, and LXRX

Should you buy Surrozen stock or one of its competitors? Surrozen's main competitors and comparable companies include Avalo Therapeutics (AVTX), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Forte Biosciences (FBRX), and Lexicon Pharmaceuticals (LXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Surrozen compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, Surrozen had 4 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Surrozen and 1 mentions for Avalo Therapeutics. Surrozen's average media sentiment score of 0.59 beat Avalo Therapeutics' score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Surrozen	Positive

Avalo Therapeutics presently has a consensus price target of $45.10, suggesting a potential upside of 128.47%. Surrozen has a consensus price target of $45.00, suggesting a potential upside of 92.64%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Avalo Therapeutics has higher earnings, but lower revenue than Surrozen. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,644.27	-$78.26M	-$4.37	N/A
Surrozen	$3.48M	77.93	-$242.03M	-$40.55	N/A

Avalo Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Surrozen	-2,885.33%	N/A	-93.62%

Avalo Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Avalo Therapeutics beats Surrozen on 10 of the 17 factors compared between the two stocks.

How does Surrozen compare to WAVE Life Sciences?

Surrozen (NASDAQ:SRZN) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Surrozen currently has a consensus target price of $45.00, suggesting a potential upside of 92.64%. WAVE Life Sciences has a consensus target price of $22.53, suggesting a potential upside of 329.13%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

WAVE Life Sciences has higher revenue and earnings than Surrozen. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	77.93	-$242.03M	-$40.55	N/A
WAVE Life Sciences	$42.73M	24.21	-$204.38M	-$1.09	N/A

In the previous week, Surrozen had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Surrozen and 3 mentions for WAVE Life Sciences. Surrozen's average media sentiment score of 0.59 beat WAVE Life Sciences' score of -0.97 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

WAVE Life Sciences has a net margin of -309.73% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Surrozen has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market.

Summary

WAVE Life Sciences beats Surrozen on 9 of the 17 factors compared between the two stocks.

How does Surrozen compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

In the previous week, Janux Therapeutics had 4 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Janux Therapeutics and 5 mentions for Surrozen. Janux Therapeutics' average media sentiment score of 0.96 beat Surrozen's score of 0.59 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has higher revenue and earnings than Surrozen. Janux Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	114.21	-$113.62M	-$1.64	N/A
Surrozen	$3.48M	77.93	-$242.03M	-$40.55	N/A

Janux Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Janux Therapeutics presently has a consensus target price of $36.46, suggesting a potential upside of 95.19%. Surrozen has a consensus target price of $45.00, suggesting a potential upside of 92.64%. Given Janux Therapeutics' higher possible upside, equities analysts clearly believe Janux Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Janux Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Surrozen	-2,885.33%	N/A	-93.62%

Summary

Janux Therapeutics beats Surrozen on 12 of the 16 factors compared between the two stocks.

How does Surrozen compare to Forte Biosciences?

Surrozen (NASDAQ:SRZN) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Surrozen and Surrozen both had 5 articles in the media. Surrozen's average media sentiment score of 0.59 beat Forte Biosciences' score of 0.38 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forte Biosciences has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Forte Biosciences	N/A	-94.82%	-77.68%

Surrozen presently has a consensus target price of $45.00, indicating a potential upside of 92.64%. Forte Biosciences has a consensus target price of $71.67, indicating a potential downside of 6.89%. Given Surrozen's stronger consensus rating and higher possible upside, equities analysts clearly believe Surrozen is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.6% of Surrozen shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Forte Biosciences has lower revenue, but higher earnings than Surrozen. Forte Biosciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	77.93	-$242.03M	-$40.55	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

Surrozen has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, meaning that its stock price is 162% more volatile than the broader market.

Summary

Surrozen beats Forte Biosciences on 9 of the 15 factors compared between the two stocks.

How does Surrozen compare to Lexicon Pharmaceuticals?

Surrozen (NASDAQ:SRZN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Surrozen has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

In the previous week, Surrozen had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Surrozen and 4 mentions for Lexicon Pharmaceuticals. Surrozen's average media sentiment score of 0.59 beat Lexicon Pharmaceuticals' score of 0.22 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Surrozen presently has a consensus price target of $45.00, suggesting a potential upside of 92.64%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 94.44%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lexicon Pharmaceuticals has higher revenue and earnings than Surrozen. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	77.93	-$242.03M	-$40.55	N/A
Lexicon Pharmaceuticals	$49.80M	20.91	-$50.34M	-$0.15	N/A

Summary

Surrozen beats Lexicon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$278.30M	$4.00B	$7.34B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-0.58	11.81	270.94	24.14
Price / Sales	77.93	1,381.12	634.77	96.69
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	-1.24	16.86	13.14	6.25
Net Income	-$242.03M	-$22.76M	$3.46B	$347.86M
7 Day Performance	-2.67%	4.71%	3.23%	1.57%
1 Month Performance	18.40%	12.26%	8.82%	5.24%
1 Year Performance	105.47%	60.84%	27.70%	17.87%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	3.1326 of 5 stars	$23.36 -2.5%	$45.00 +92.6%	+113.6%	$278.30M	$3.48M	N/A	80
AVTX Avalo Therapeutics	2.4295 of 5 stars	$20.61 +4.6%	$45.10 +118.8%	+95.0%	$1.10B	$60K	N/A	40
WVE WAVE Life Sciences	2.8033 of 5 stars	$5.48 +3.5%	$22.53 +311.5%	-49.6%	$1.08B	$42.73M	N/A	240
JANX Janux Therapeutics	2.8863 of 5 stars	$17.67 +4.2%	$37.58 +112.7%	-23.5%	$1.08B	$24M	N/A	30	Analyst Upgrade
FBRX Forte Biosciences	1.6076 of 5 stars	$76.94 +0.1%	$71.67 -6.8%	+573.2%	$1.07B	N/A	N/A	5	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. AVTX, WVE, JANX, FBRX, and LXRX

How does Surrozen compare to Avalo Therapeutics?

Summary

How does Surrozen compare to WAVE Life Sciences?

Summary

How does Surrozen compare to Janux Therapeutics?

Summary

How does Surrozen compare to Forte Biosciences?

Summary

How does Surrozen compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. AVTX, WVE, JANX, FBRX, and LXRX

How does Surrozen compare to Avalo Therapeutics?

Does the media prefer AVTX or SRZN?

Do analysts recommend AVTX or SRZN?

Which has better earnings and valuation, AVTX or SRZN?

Is AVTX or SRZN more profitable?

Which has more risk and volatility, AVTX or SRZN?

Do insiders and institutionals have more ownership in AVTX or SRZN?

Summary

How does Surrozen compare to WAVE Life Sciences?

Do analysts rate SRZN or WVE?

Which has preferable valuation & earnings, SRZN or WVE?

Does the media favor SRZN or WVE?

Do institutionals & insiders hold more shares of SRZN or WVE?

Is SRZN or WVE more profitable?

Which has more volatility & risk, SRZN or WVE?

Summary

How does Surrozen compare to Janux Therapeutics?

Does the media prefer JANX or SRZN?

Which has stronger valuation and earnings, JANX or SRZN?

Which has more risk & volatility, JANX or SRZN?

Do institutionals & insiders have more ownership in JANX or SRZN?

Do analysts rate JANX or SRZN?

Is JANX or SRZN more profitable?

Summary

How does Surrozen compare to Forte Biosciences?

Does the media prefer SRZN or FBRX?

Is SRZN or FBRX more profitable?

Do analysts recommend SRZN or FBRX?

Do institutionals & insiders hold more shares of SRZN or FBRX?

Which has higher valuation & earnings, SRZN or FBRX?

Which has more volatility and risk, SRZN or FBRX?

Summary

How does Surrozen compare to Lexicon Pharmaceuticals?

Which has more volatility and risk, SRZN or LXRX?

Does the media prefer SRZN or LXRX?

Do institutionals & insiders hold more shares of SRZN or LXRX?

Is SRZN or LXRX more profitable?

Do analysts prefer SRZN or LXRX?

Which has better valuation and earnings, SRZN or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools